I am confused. Is the self-imposed quite period in reference to the JA or because of the submission of data for review to the 4 regulators. NWBO has only 1 author/employee (Bosch) on the authors list. Other than that, the Doctors are sharing "New" trial results with the medical community.
The top Brass at NWBO have decided at the end of the PH3 to remain quite till approval and that time line is well beyond their control as we have experienced. The only communication is what the Regulatory Authority in the UK has told them to accomplish. Being able to provide the product (DCvax) to the medical community of the UK and PIP trial.
To me, dilution is keeping on the lights, required expansion, and new required study trials (PIP).
I really do not see how anyone can not think this product will not get approval this week or this coming year, it will happen, but it is in the hands or others at this point.
I am not her for the short term. I will be here till I lose it all or it will be a life changing event for my children and grand kids. If I lose it all, it will not change the rest of my life as I am a simple man.
Market Data 
Markets 
AI
